Member Info for Mulder

I understand we should be hearing news about the spin off very soon. Chance of a bid also. Should see a sharp re-rating upwards.

Strange how the SP here tends to rise when the market gets battered. Shows how controlled and manipulated the SP is here by the shorters.

SP has lost about 60% in the past 12 months. SIXTY PERCENT. I feel for those with high averages and holdings. You have a right to ask to speak directly to the hierarchy and CEO. The board must feel shareholders' wrath. As for the FCA this was 1200p only last week. A 12% swing in a week on the back of no news? Rogue.

Hikma Pharmaceuticals PLC 1 New Burlington Place, London W1S 2H Tel: +44 (0) 20 7399 2760 Fax: +44 (0) 20 7399 2761 Email: investors@hikma.uk.com

How many of you have contacted them? Those with large holdings here should especially be as a minimum be emailing or speaking to them and the CEO. Lack of director buys and a possible sale/buy out would be at the top of the agenda.

Not sure where 9 is coming from. Support around 1045p and then 1015-1020p

Trading at a steep discount to the book price and on a P/E around 10 which is cheap.

Another dive today

An extra $104M+ from this PPI product helps. Important to remember that H1 figures were not that bad at all with revenue and profits still showing growth just less than the market were expecting. A return to growth However, I think it could be time to revisit Hikma and today�s announcement makes interesting reading. The company�s wholly-owned US subsidiary West-Ward Pharmaceuticals Corp. has launched Pantoprazole Sodium for Injection, which treats gastroesophageal reflux disease. Hikma reckons that, according to market insight company IMS Health, US sales of Pantoprazole Sodium for Injection were around $104m for the year to August. Chief executive of the Injectables division, Riad Mechlaoui, said the launch of the product will help reduce shortages in the US market, so it looks like the launch could be a shrewd move by the company with the potential to kick-start renewed growth. More product launches look set to follow in due course. Mr Mechlaoui tells us that Hikma is executing its Injectables pipeline and using the additional capacity it has been adding to its Portuguese facility to support future growth. **City analysts following Hikma expect earnings to reverse the decline of recent years by putting on 10% during 2018. Meanwhile, the share price remains depressed and I think it could be worth examining the investment opportunity right now.

Hard to believe but a hedge fund is short selling Spire (!) and they have been increasing their position in recent days. PSquared asset management - what do they know? https://shorttracker.co.uk/company/GB00BNLPYF73/

Hikma Pharmaceuticals (LSE: HIK) has had a tough period. The company has recorded a share price decline of 41% in the last year as a profit warning has hurt investor sentiment in the stock. That was caused by pricing pressures which it expects to last into 2018. This means that a quick recovery in its share price may not be on the cards. However, after a forecast fall in earnings of 20% in the current year, Hikma is expected to record a rise in its bottom line of 10% next year.** This could help to boost investor sentiment � especially since it now trades on a relatively low valuation. ***For example, the stock has a price-to-earnings growth (PEG) ratio of just 1.5 and this suggests that a wide margin of safety could be on offer. Certainly, the company�s near term outlook is challenging. And there is a risk that the pricing pressures it is experiencing could last over the medium term. However, with a low valuation and a fundamentally sound business model, it could deliver improving share price performance in the long run. Therefore, now could be the perfect time to buy a slice of it. http://www.fool.co.uk/investing/2017/10/18/2-growth-stocks-for-the-long-run/

The data below just highlights again the strength of Hikma's balance sheet especially compared to others in this sector. GSK Assets �59Bn Intangibles/goodwill �25Bn [42%] Liabilities �54Bn Net Assets �5Bn Shareholder equity - intangibles/goodwill = -�20Bn AZN Assets �62.5Bn Intangibles/goodwill �39Bn [62%] Liabilities �46Bn Net Assets �16.5Bn Shareholder equity - intangibles/goodwill = -�22Bn HIKMA Assets �4.4Bn Intangibles/goodwill �1.7Bn [39%] Debt �1.9Bn Net Assets �2.5Bn Shareholder equity - intangibles/goodwill = +�0.8Bn

The FT article from last week said Ashley had to buy back millions of shares in October and November at 66p. Bizarre then that the SP fell 10% last week. Ashley's options are complex but it does appear he is increasing his stake here. Given the current SP any offer around the book price of 75p would most likely be accepted. Bear in mind that most M&A premiums are around 30%

So trading at almost half its book price. Quite some discount. Word of caution is a lot of intangibles/goodwill so depends on how much the brands they own are really worth.

This is the government we are dealing with though and this Tory government is capable of anything. Just look at the energy cap proposals. Uncertainty in the budget re: green subsidies must be removed.

The Professor from Oxford Mr Helm published a report for the Government suggesting nationalising National Grid and the wider energy industry. He also said the green subsidies such as the one Drax gets is far too high and must be cut. I am a holder here but that uncertainty is why SP is dropping IMO. Importing wood chips from America to burn here is crazy. The Tories are desperate to save money. We need reassurance in the budget re: Drax subsidies.

Do not trust the buys and sells data. It is misleading and proven to be inaccurate. I have done this by checking my own trades. Even million pound trades are often misreported. It is yet another anomaly of the rogue stock market. The computer 'decides' whether or not to record it as a buy or sell. I've said this on other boards but maybe not here

Trading at book price and >�90M in cash.

The problem Fruister is the negative sentiment caused by the 13% shorts and how they can seemingly 'control' the SP. I have highlighted this before. If this breaches 40p then 32p could be on the cards. It seems they don't care about fundamentals or the P/E which could drop to 1 for all they care. A 10% fall this week is terrible - based on what? Annual results were last week! How the FCA allows this BS to go on is a mystery.

The wild swings continue then. Crazy given the sector this share is in. I hope the rumours of a bid come true. Wall Street Wires has a good track record. SEPTEMBER 14th 2017 The spin from in and around the company is that it is remodelling itself into a clean, green corporate machine. While we may take this with a pinch of salt, the new look is apparently attracting M&A attention from parties as diverse as the Chinese Government, GDF Suez and RWE to name a few. Massive NAV Discount Underpinning the idea of tucking away some Drax shares with or without the alleged interested parties, is the way that the NAV of the company is up at 460p even before the latest turnaround moves.The company is already on the M&A radar of Credit Suisse This compares with the present share price of 315p, a sharp contrast to the 800p plus only last year. The implication of the NAV value is that even a lowball takeover here of 500p � the present City rumour, would do very nicely for bottom fishers entering the fray at present levels. https://wallstreetwires.com/drax-takeover-save-woodfords-reputation/ IMO it all depends on Tories and their subsidy amounts